Organogenesis Holdings Inc. (NASDAQ: ORGO) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $105M. The Maz Rating grades it against the other companies in its sector.
Organogenesis Holdings Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.81, Organogenesis Holdings Inc. trades at 0.3x sales and 0.9x book value. Over the last twelve months it generated about $351M of revenue and a net loss of $153M. It runs a gross margin of 62.0%, an operating margin of -22.8% and a net margin of -40.2%. It shows return on equity of -46.3%, return on invested capital of -24.3% and a free cash flow yield of -0.1%. On the balance sheet: a debt-to-equity ratio of 0.54 and a current ratio of 3.32. Over the past 52 weeks the share price ranged from $0.73 to $5.99, with a beta of 1.27.
Organogenesis Holdings Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 4 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.